ABSTRACT
INTRODUCTION
nflammation plays an integral role in the 1 Ipat hogenesis of cardiovascular events.
One of the potential inflammatory markers is C-reactive protein (CRP), an acute phase substance that shows extent of inflammation and has proved to be an independent as well as a combined risk factor in a number of cardiovascular Among the pharmaceutical interventions, statins are the best choice for cardiovascular diseases so far. Apart from their hypolipidemic action, they also 5 exert anti-inflammatory actions by stimu latin g the expression of peroxisome proliferator-activated receptor 6 gamma(PPAR-). Gemfibrozil, a PPAR aagonist, is also used as a cholesterol lowering-agent. Since its approval by the FDA in 1982, it has been used extensively as a lipid regulating drug and is an effective treatment of hypertriglyceridemia and 7 hypercholesterolemia.
Pioglitazone is a member of the thiazolidinediones (TZDs) family of antidiabetic agent that stimulates the peroxisome proliferator-activated receptor-y and a. In addition to its beneficial effects on glucose and lipid metabolism, this gene has multiple effects 8 including anti-inflammatory properties. Clinical studies have shown that it is able to reduce inflammatory markers such as CRP in diabetic as well as non-diabetic 9, 10 patients.
Activation of PPAR-y by pioglitazone as well as simvastatin reduce the inflammatory markers in patients of ischemic heart disease with metabolic Level of CRP in all groups was similar at 0 week. After high fat diet it increased in all th groups at 4 week. After treatment with th pioglitazone it decreased at 8 week but continued to increase in control and gemfibrozil treated groups (Table I) .
RESULTS
Multiple comparisons by ANOVA revealed significant difference between groups th at 8 week only. Post hoc analysis disclosed that CRP level was significantly low is pioglitazone treated group compared to control and gemfibrozil groups. While difference between control and gemfibrozil was not significant (Table II) .
When repeat measure ANOVA was applied p value was <0.001 in each group (Table I) . Post hoc analysis of each group revealed significant increase in CRP level from 0-4 and 0-8 weeks in all groups. From 4-8 week there was significant decrease in pioglitazone treated group, while significant increase in control and gemfibrozil treated group (Table III) .
Blood sugar level was only measured at th 4 week to exclude diabetic rats, however; none of the rats developed diabetes. This th test was not repeated at 8 week.
Silent inflammation causes a significant contribution to the pathogenesis as well 15 as complications of atherosclerosis and poses an enormous burden on public health system. There are several markers to detect this inflammation out of which the role of CRP cannot be denied. It has a long half-life of 19 hours, due to which it is a stable marker for cardiovascular status monitoring. It plays an important role in detecting subclinical diseases and assessing 16 the wellbeing of average population. Results of this study demonstrate probable anti-inflammatory role of pioglitazone, evidenced by significant decrease in CRP level in non-diabetic hyperlipidemic rats in presence of continued high fat feeding while gemfibrozil is not effective.
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